pour la recherche uniquement

Salinomycin (Procoxacin) Wnt/beta-catenin inhibiteur

Name: Salinomycin (Procoxacin)
Brand: Selleck Chemicals
SKU: S8129
Rating: 5 (22 reviews)

Réf. CatalogueS8129

Le Salinomycin, traditionnellement utilisé comme anticoccidien, s'est récemment avéré posséder des effets anticancéreux et anti-cellules souches cancéreuses (CSC).

Salinomycin (Procoxacin) Wnt/beta-catenin inhibiteur Chemical Structure

Structure chimique

Poids moléculaire: 751.00

Aller à

Contrôle qualité

Lot : Pureté: >97%

Cité dans Nature Medicine pour sa qualité supérieure
COA
Fiche technique
SDS

Cité dans Nature Medicine pour sa qualité supérieure
COA
NMR
Fiche technique
SDS

Cité dans Nature Medicine pour sa qualité supérieure
COA
Microanalyse

Pourquoi la microanalyse ?
Fiche technique
SDS

Cibles apparentées	JAK TGF-beta/Smad ERK GSK-3 ROCK Hedgehog/Smoothened PKA Secretase STAT Casein Kinase
Autre Wnt/beta-catenin Inhibiteurs	IWR-1-endo PRI-724 (Foscenvivint) IWP-2 Tegatrabetan (BC-2059) Isoquercitrin ICG-001 SKL2001 BML-284 Hydrochloride (Wnt agonist 1, AMBMP) PNU-74654 FH535

Culture cellulaire, traitement et concentration de travail

Lignées cellulaires	Type dessai	Concentration	Temps dincubation	Description de lactivité	PMID
HL60 cells	Proliferation assay		72 h	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.29 μM	25644674
MV4-11 cells	Proliferation assay		72 h	Antiproliferative activity against human MV4-11 cells after 72 hrs, IC50=0.33 μM	26163197
LoVo cells	Proliferation assay		72 h	Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method, IC50=0.36 μM	25644674
VCaP cells	Proliferation assay			Antiproliferative activity against human VCaP cells, EC50=0.38 μM	23063400
LS180 cells	Proliferation assay		72 h	Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method, IC50=0.61 μM	25644674
HT-29 cells	Proliferation assay		72 h	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method, IC50=1.03 μM	25644674
SW707 cells	Proliferation assay		72 h	Antiproliferative activity against human SW707 cells assessed as growth inhibition after 72 hrs by SRB method, IC50=1.73 μM	25644674
HL60/Vinc cells	Cytotoxicity assay		72 h	Cytotoxicity against vincristine-resistant human HL60/Vinc cells incubated for 72 hrs by MTT assay, IC50=3.44 μM	23079523
BALB/3T3 cells	Cytotoxicity assay		72 h	Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay, IC50=28.08 μM	23079523
VCaP	Antiproliferative assay			Antiproliferative activity against human VCaP cells, EC50 = 0.38 μM.	23063400
HL60	Cytotoxicity assay		72 hrs	Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay, IC50 = 0.44 μM.	23079523
LoVo	Cytotoxicity assay		72 hrs	Cytotoxicity against human LoVo cells incubated for 72 hrs by MTT assay, IC50 = 1.11 μM.	23079523
HL60/Vinc	Cytotoxicity assay		72 hrs	Cytotoxicity against vincristine-resistant human HL60/Vinc cells incubated for 72 hrs by MTT assay, IC50 = 3.44 μM.	23079523
LoVo/DX	Cytotoxicity assay		72 hrs	Cytotoxicity against doxorubicin-resistant human LoVo/DX cells incubated for 72 hrs by MTT assay, IC50 = 6.23 μM.	23079523
BALB/3T3	Cytotoxicity assay		72 hrs	Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay, IC50 = 28.08 μM.	23079523
LoVo/DX	Antiproliferative assay			Antiproliferative activity against human LoVo/DX cells, IC50 = 1 μM.	24631190
HL60	Antiproliferative assay			Antiproliferative activity against human HL60 cells, IC50 = 1.2 μM.	24631190
LoVo	Antiproliferative assay			Antiproliferative activity against human LoVo cells, IC50 = 1.5 μM.	24631190
HL60/Vinc	Antiproliferative assay			Antiproliferative activity against human HL60/Vinc cells, IC50 = 4.7 μM.	24631190
BALB/3T3	Antiproliferative assay			Antiproliferative activity mouse BALB/3T3 cells, IC50 = 25.8 μM.	24631190
HL60	Antiproliferative assay		72 hrs	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.29 μM.	25644674
LoVo	Antiproliferative assay		72 hrs	Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method, IC50 = 0.36 μM.	25644674
LS180	Antiproliferative assay		72 hrs	Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method, IC50 = 0.61 μM.	25644674
LoVo/DX	Antiproliferative assay		72 hrs	Antiproliferative activity against human doxorubicin-resistant LoVo/DX cells assessed as growth inhibition after 72 hrs by SRB method, IC50 = 0.76 μM.	25644674
HT-29	Antiproliferative assay		72 hrs	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method, IC50 = 1.03 μM.	25644674
SW707	Antiproliferative assay		72 hrs	Antiproliferative activity against human SW707 cells assessed as growth inhibition after 72 hrs by SRB method, IC50 = 1.73 μM.	25644674
HL60/Vinc	Antiproliferative assay		72 hrs	Antiproliferative activity against human vincristine-resistant HL60/Vinc cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 2.09 μM.	25644674
BALB/3T3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method, IC50 = 9.33 μM.	25644674
MV4-11	Antiproliferative assay		72 hrs	Antiproliferative activity against human MV4-11 cells after 72 hrs, IC50 = 0.33 μM.	26163197
LoVo	Antiproliferative assay		72 hrs	Antiproliferative activity against human LoVo cells after 72 hrs, IC50 = 0.53 μM.	26163197
LoVo/DX	Antiproliferative assay		72 hrs	Antiproliferative activity against doxorubicin-resistant human LoVo/DX cells after 72 hrs, IC50 = 0.59 μM.	26163197
BALB/3T3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs, IC50 = 27.76 μM.	26163197
JIMT1	Cytotoxicity assay		72 hrs	Cytotoxicity against human JIMT1 cells after 72 hrs by MTT assay, IC50 = 0.52 μM.	27326340
MCF7	Cytotoxicity assay		72 hrs	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 0.59 μM.	27326340
MCF7	Antiproliferative assay		48 hrs	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 2.98 μM.	27876192
MDA-MB-231	Antiproliferative assay		48 hrs	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 6.42 μM.	27876192
MIAPaCa2	Cytotoxicity assay		48 hrs	Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell viability after 48 hrs by MTS assay	28177244
DU145	Cytotoxicity assay		48 hrs	Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 48 hrs by MTS assay	28177244
BT474	Cytotoxicity assay		48 hrs	Cytotoxicity against human BT474 cells assessed as decrease in cell viability after 48 hrs by MTS assay	28177244
MDA-MB-231	Cytotoxicity assay		48 hrs	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTS assay	28177244
HT-29	Cytotoxicity assay		48 hrs	Cytotoxicity against human HT-29 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay, IC50 = 1.43 μM.	28262526
HGC27	Cytotoxicity assay		48 hrs	Cytotoxicity against human HGC27 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay, IC50 = 2.57 μM.	28262526
MDA-MB-231	Cytotoxicity assay		48 hrs	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay, IC50 = 6.53 μM.	28262526
OV2008	Cytotoxicity assay		72 hrs	Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 3.2 μM.	28651817
OV2008	Cytotoxicity assay		48 hrs	Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay, IC50 = 4.78 μM.	28651817
OV2008	Cytotoxicity assay		24 hrs	Cytotoxicity against human OV2008 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 7.44 μM.	28651817
HT-29	Antiproliferative assay		48 hrs	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay, IC50 = 1.43 μM.	28688275
HEK293	Cytotoxicity assay		72 hrs	Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 0.195 μM.	29466777
HEK293	Cytotoxicity assay		72 hrs	Cytotoxicity against doxycycline inducible T-Rex/K-Ras G12V HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 0.3295 μM.	29466777
HL60	Cytotoxicity assay		48 hrs	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTS assay, IC50 = 0.58 μM.	29466777
SW480	Cytotoxicity assay		48 hrs	Cytotoxicity against human SW480 cells assessed as cell growth inhibition after 48 hrs by MTS assay, IC50 = 3.77 μM.	29466777
4T1	Cytotoxicity assay		48 hrs	Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTS assay, IC50 = 3.78 μM.	29466777
A549	Cytotoxicity assay		48 hrs	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTS assay, IC50 = 3.98 μM.	29466777
HeLa	Cytotoxicity assay		48 hrs	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTS assay, IC50 = 4.49 μM.	29466777
MCF7	Cytotoxicity assay		48 hrs	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTS assay, IC50 = 9.08 μM.	29466777
SMMC7721	Cytotoxicity assay		48 hrs	Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 48 hrs by MTS assay, IC50 = 12.04 μM.	29466777
BEAS2B	Cytotoxicity assay		48 hrs	Cytotoxicity against human BEAS2B cells assessed as cell growth inhibition after 48 hrs by MTS assay, IC50 = 13.07 μM.	29466777
LoVo	Antiproliferative assay		72 hrs	Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay, IC50 = 0.44 μM.	30025346
LoVo/DX	Antiproliferative assay		72 hrs	Antiproliferative activity against human LoVo/DX cells after 72 hrs by SRB assay, IC50 = 0.69 μM.	30025346
SK-BR-3	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-BR-3 cells after 72 hrs by SRB assay, IC50 = 0.89 μM.	30025346
JIMT1	Antiproliferative assay		72 hrs	Antiproliferative activity against human JIMT1 cells after 72 hrs by SRB assay, IC50 = 1.3 μM.	30025346
MCF7	Antiproliferative assay		72 hrs	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay, IC50 = 1.5 μM.	30025346
ALL5	Antiproliferative assay		120 hrs	Antiproliferative activity against human ALL5 cells after 120 hrs by MTT assay, IC50 = 2.4 μM.	30025346
MCF10A	Antiproliferative assay		72 hrs	Antiproliferative activity against human MCF10A cells after 72 hrs by SRB assay, IC50 = 46 μM.	30025346
HMLER	Antiproliferative assay			Antiproliferative activity against HMLER cells by MTT assay Breast cancer stem cell, IC50 = 0.1 μM.	30684870
HeLa	Antiproliferative assay			Antiproliferative activity against human HeLa cells by MTT assay, IC50 = 0.32 μM.	30684870
LoVo	Antiproliferative assay			Antiproliferative activity against human LoVo cells by SRB assay, IC50 = 0.44 μM.	30684870
JIMT1	Antiproliferative assay			Antiproliferative activity against human JIMT1 cells, IC50 = 0.52 μM.	30684870
JIMT1	Antiproliferative assay			Antiproliferative activity against human JIMT1 cells by MTT assay, IC50 = 0.52 μM.	30684870
MCF7	Antiproliferative assay			Antiproliferative activity against human MCF7 cells by MTT assay, IC50 = 0.59 μM.	30684870
LoVo/DX	Antiproliferative assay			Antiproliferative activity against human LoVo/DX cells by SRB assay, IC50 = 0.69 μM.	30684870
SKBR3	Antiproliferative assay			Antiproliferative activity against human SKBR3 cells by SRB assay, IC50 = 0.89 μM.	30684870
HT-29	Antiproliferative assay			Antiproliferative activity against human HT-29 cells by MTT assay, IC50 = 1.03 μM.	30684870
JIMT1	Antiproliferative assay			Antiproliferative activity against human JIMT1 cells by SRB assay, IC50 = 1.3 μM.	30684870
MCF7	Antiproliferative assay			Antiproliferative activity against human MCF7 cells by SRB assay, IC50 = 1.5 μM.	30684870
HGC27	Antiproliferative assay			Antiproliferative activity against human HGC27 cells by MTT assay, IC50 = 2.57 μM.	30684870
HT-29	Antiproliferative assay		48 hrs	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay, IC50 = 3.21 μM.	30684870
4T1	Antiproliferative assay			Antiproliferative activity against mouse 4T1 cells by MTT assay, IC50 = 3.78 μM.	30684870
A549	Antiproliferative assay			Antiproliferative activity against human A549 cells by MTT assay, IC50 = 3.98 μM.	30684870
MDA-MB-231	Antiproliferative assay			Antiproliferative activity against human MDA-MB-231 cells by SRB assay, IC50 = 6.42 μM.	30684870
MDA-MB-231	Antiproliferative assay			Antiproliferative activity against human MDA-MB-231 cells by MTT assay, IC50 = 6.91 μM.	30684870
HGC27	Antiproliferative assay		48 hrs	Antiproliferative activity against human HGC27 cells after 48 hrs by MTT assay, IC50 = 8.18 μM.	30684870
Caco2	Antiproliferative assay			Antiproliferative activity against human Caco2 cells by MTT assay, IC50 = 12.99 μM.	30684870
U87	Antiproliferative assay			Antiproliferative activity against human U87 cells by MTT assay, IC50 = 38.7 μM.	30684870
MCF10A	Antiproliferative assay			Antiproliferative activity against human MCF10A cells by SRB assay, IC50 = 46 μM.	30684870
HepG2	Cytotoxicity assay		72 hrs	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 24.5 μM.	30871771
HL60	Cytotoxicity assay		24 hrs	Cytotoxicity against human HL60 cells assessed as growth inhibition after 24 hrs by resazurin dye based assay, GI50 = 6.63 μM.	30986574
HL-60	Function assay		24 hrs	Trypanocidal activity against bloodstream forms of Trypanosoma brucei infected in human HL-60 cells incubated for 24 hrs followed by compound wash out after 72 hrs, GI50 = 0.18 μM.	31103901
MDCK	Antiviral assay		3 days	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells after 3 days by MTT assay, EC50 = 0.4 μM.	31103901
Vero	Antiviral assay		24 hrs	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr, IC50 = 0.24 μM.	ChEMBL
MIAPaCa2	Cytotoxicity assay		48 hrs	Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTS assay, CC50 = 6.5 μM.	ChEMBL
BT474	Cytotoxicity assay		48 hrs	Cytotoxicity against human BT474 cells after 48 hrs by MTS assay, CC50 = 14 μM.	ChEMBL
BT474	Function assay	7.5 uM	3 days	Disruption of preformed spheroids in human BT474 cancer stem cells at 7.5 uM after 3 days by microscopic analysis	ChEMBL
DU145	Function assay	7.5 uM	3 days	Disruption of preformed spheroids in human DU145 cancer stem cells at 7.5 uM after 3 days by microscopic analysis	ChEMBL
Cliquez pour voir plus de données expérimentales sur la lignée cellulaire

Informations chimiques, stockage et stabilité

Poids moléculaire	751.00	Formule	C₄₂H₇₀O₁₁	Stockage (À compter de la date de réception)	3 ans-20°Cpoudre
N° CAS	53003-10-4	Télécharger le SDF		Stockage des solutions mères	1 an-80°Cen solvant 1 mois-20°Cen solvant
Synonymes	Procoxacin			Smiles	CCC(C1CCC(C(O1)C(C)C(C(C)C(=O)C(CC)C2C(CC(C3(O2)C=CC(C4(O3)CCC(O4)(C)C5CCC(C(O5)C)(CC)O)O)C)C)O)C)C(=O)O

Solubilité

In vitro
Lot:

DMSO : 100 mg/mL (133.15 mM)
(Le DMSO contaminé par lhumidité peut réduire la solubilité. Utiliser du DMSO frais et anhydre.)

Ethanol : 100 mg/mL

Water : Insoluble

Calculateur de molarité

Masse	Concentration	Volume	Poids moléculaire
=	×	×

Calculateur de dilution Calculateur de poids moléculaire

In vivo Lot:
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validé par les laboratoires Selleck. Si vous avez besoin dajustements à cette formulation, contactez notre équipe commerciale pour des tests personnalisés.	5.000mg/ml (6.66mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validé par les laboratoires Selleck. Si vous avez besoin dajustements à cette formulation, contactez notre équipe commerciale pour des tests personnalisés.	2.500mg/ml (3.33mM)	Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 Corn oil Validé par les laboratoires Selleck. Si vous avez besoin dajustements à cette formulation, contactez notre équipe commerciale pour des tests personnalisés.	2.500mg/ml (3.33mM)	Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Calculateur de formulation in vivo (Solution claire)

Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant lexpérience)

Dosage : mg/kg Poids moyen des animaux : g Volume de dosage par animal :μL Nombre danimaux :

Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter dabord sil ny a pas de formulation in vivo dans la section Solubilité.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Résultats du calcul :

Concentration de travail : mg/ml;

Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter dabord si la concentration dépasse la solubilité du DMSO du lot de médicament. )

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH₂O, mélanger et clarifier.

Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.

Note : 1. Veuillez vous assurer que le liquide est clair avant dajouter le solvant suivant.
2. Assurez-vous dajouter le(s) solvant(s) dans lordre. Vous devez vous assurer que la solution obtenue, lors de lajout précédent, est une solution claire avant de procéder à lajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.

Mécanisme daction

Targets/IC₅₀/Ki	Wnt/β-catenin
In vitro	Le Salinomycin, un antibiotique ionophore polyéther isolé de Streptomyces albus, a été montré pour tuer les CSC dans différents types de cancers humains, très probablement en interférant avec les transporteurs de médicaments ABC (ATP-binding cassette), la voie de signalisation Wnt/beta-catenin et d'autres voies de CSC. Il présente une activité antimicrobienne contre les bactéries Gram-positives, y compris Bacillus subtilis, Staphylococcus aureus, Micrococcus flavus, Sarcina lutea, Mycobacterium spp., certains champignons filamenteux, Plasmodium falciparum et Eimeria spp., parasites protozoaires responsables de la coccidiose chez la volaille. De plus, ce composé a été montré très tôt pour agir dans différentes membranes biologiques, y compris les membranes cytoplasmiques et mitochondriales, comme un ionophore de cations monovalents avec une sélectivité stricte pour les ions alcalins et une forte préférence pour le K+, favorisant ainsi l'efflux mitochondrial et cytoplasmique de K+ et inhibant la phosphorylation oxydative. Le Salinomycin peut induire une apoptose massive dans les cellules cancéreuses humaines d'origines différentes qui présentent de multiples mécanismes de résistance aux médicaments et à l'apoptose.
In vivo	Salinomycin (from Streptomyces albus) est capable d'éliminer efficacement les CSC et d'induire une régression clinique partielle des cancers lourdement prétraités et résistants à la thérapie. Il a également été démontré comme un agent inotrope et chronotrope positif qui a augmenté le débit cardiaque, la pression systolique ventriculaire gauche, la fréquence cardiaque, la pression artérielle moyenne, la vasodilatation et le flux sanguin des artères coronaires, et la concentration plasmatique de catécholamines. Ces résultats ont été obtenus lors d'expériences avec des chiens bâtards ayant reçu une seule injection intraveineuse de 150 µg/kg de ce composé. Cependant, une toxicité considérable du salinomycin a été rapportée chez les mammifères, tels que les chevaux, les porcs, les chats et les alpagas après une ingestion orale ou inhalative accidentelle. Les données d'évaluation des risques récemment publiées par l'Autorité européenne de sécurité des aliments déclarent une dose journalière admissible (DJA) de 5 µg/kg de salinomycin pour les humains, car une prise quotidienne de plus de 500 µg/kg de salinomycin par les chiens entraîne des effets neurotoxiques, tels que la perte de myéline et la dégénérescence axonale. L'administration intraveineuse de 200 à 250 µg/kg de salinomycin tous les deux jours pendant trois semaines entraîne une régression partielle des métastases tumorales et ne montre que des effets secondaires aigus et à long terme mineurs, mais aucun effet secondaire grave aigu et à long terme observé avec les médicaments chimiothérapeutiques conventionnels.
Références	[1] https://pubmed.ncbi.nlm.nih.gov/23251084/ [2] https://pubmed.ncbi.nlm.nih.gov/23028492/ [3] https://pubmed.ncbi.nlm.nih.gov/23338561/

Support technique

Instructions de manipulation

Tel: +1-832-582-8158 Ext:3

Si vous avez dautres questions, veuillez laisser un message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):